Superficial bladder cancer. Risk of recurrence and potential role for interferon therapy

Cancer

Volumn 59, Issue 3 S, 1987, Pages 613-616

  Torti, Frank M ^a,b,c   Pharmd, Bert L Lum ^a,b,c  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF THE PACIFIC   (United States)

^c VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; BCG VACCINE; INTERFERON; POLYINOSINIC POLYCYTIDYLIC ACID; RECOMBINANT ALPHA2B INTERFERON;

BLADDER; BLADDER CANCER; CANCER CHEMOTHERAPY; CARCINOMA IN SITU; DRUG EFFICACY; HUMAN; PRIORITY JOURNAL; RISK FACTOR; SHORT SURVEY; THERAPY; TUMOR RECURRENCE;

ADMINISTRATION, INTRAVESICAL; BLADDER NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, TRANSITIONAL CELL; CLINICAL TRIALS; HUMAN; INTERFERONS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, MULTIPLE PRIMARY; RISK;

EID: 0023093727     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/1097-0142(19870201)59:3+<613::AID-CNCR2820591307>3.0.CO;2-3     Document Type: Article

References (36)

1. The biology and treatment of superficial bladder cancer
2. Cancer statistics
3. Cancer of the bladder
4. Superficial carcinoma of the bladder: Natural history and the role of interferons
5. Benign papilloma or papillary carcinoma of the bladder?
6. T1 bladder tumors
7. Papilloma of the urinary bladder
8. Report of a follow‐up of papillary tumors of the bladder
9. The natural history of superficial bladder tumors (Abstr)
10. Total cystectomy for bladder tumors
11. The plight of the patient with carcinoma in situ of the bladder
12. Factors influencing the recurrence rate of bladder cancer
13. Epithelioma of the genitourinary organs
14. Survival following transurethral resection of bladder carcinoma
15. Prognostic parameters in superficial bladder cancer: An analysis of 315 cases
16. Non‐invasive papillary carcinoma of the bladder associated with carcinoma in situ
17. Randomized trial of standardized therapy with or without Poly I:C in patients with superficial bladder cancer
18. Therapeutic approaches including interferon to carcinoma in situ of the bladder
19. Bladder tumors and associated proliferative mucosal lesions
20. The association of urothelial atypism with neoplasia: Its importance in treatment and prognosis
21. Serial multiple‐site biopsies in patients with bladder cancer
22. Morphological and clinical observations of patients with early bladder cancer treated with total cystectomy
23. Clinical observations on 69 cases of in situ carcinoma of the urinary bladder
24. Impaired immunologic reactivity and recurrence following cancer surgery
25. Immunologic unreactivity in bladder cancer patients
26. ABO antigens in cancer: Detection with mixed cell agglutination reaction
27. Prognostic value of cell surface antigens using immunoperioxidase methods in bladder carcinoma
28. Blood group precursor T‐antigen expression in human bladder carcinoma
29. A, B, H antigens in transitional cell tumors of the urinary bladder
30. Blood group antigens and bladder carcinoma: A perspective
31. Application of human leukocyte interferon in patients with urinary bladder papillomatosis, breast cancer and melanoma
32. Systemic IFN‐alpha treatment of multiple papilloma grade I or II patients: Pilot study
33. Superficial bladder cancers are responsive to alpha‐2 interferon administered intravesically (Abstr)
34. Intravesical interferon therapy for carcinoma in situ and transitional cell carcinoma of the bladder (Abstr)